Evidence map›Paper›PMID 39532538›Full record

ArticleLife science alliance2025

Divergent roles of RIPK3 and MLKL in high-fat diet-induced obesity and MAFLD in mice.

Hazel Tye, Stephanie A Conos, Tirta M Djajawi, Timothy A Gottschalk, Nasteho Abdoulkader, Isabella Y Kong, Helene L Kammoun, Vinod K Narayana, Tobias Kratina, Mary Speir and 18 more

Abstract read
In one paragraph

Article in Life science alliance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. RIPK3 Orchestrates Scar-Associated Macrophage Dysfunction to Drive Pulmonary Fibrosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Hazel TyeCentre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Australia.
Stephanie A ConosCentre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Australia.ORCID 0000-0003-4268-7886
Tirta M DjajawiCentre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Australia.
Timothy A GottschalkCentre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Australia.ORCID 0000-0002-7953-5555
Nasteho AbdoulkaderCentre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Australia.ORCID 0000-0002-7049-7345
Isabella Y KongThe Walter and Eliza Hall Institute of Medical Research, Parkville, Australia.
Helene L KammounBaker Heart and Diabetes Institute, Melbourne, Australia.
Vinod K NarayanaMetabolomics Australia, Bio21 Institute of Molecular Science and Biotechnology, University of Melbourne, Melbourne, Australia.ORCID 0000-0003-3980-7496
Tobias KratinaPeter MacCallum Cancer Centre, Melbourne, Australia.
Mary SpeirCentre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Australia.
Jack EmeryCentre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Australia.
Daniel S SimpsonThe Walter and Eliza Hall Institute of Medical Research, Parkville, Australia.
Cathrine HallThe Walter and Eliza Hall Institute of Medical Research, Parkville, Australia.
Angelina J VinceThe Walter and Eliza Hall Institute of Medical Research, Parkville, Australia.
Sophia RussoThe Walter and Eliza Hall Institute of Medical Research, Parkville, Australia.
Rhiannan CrawleyThe Walter and Eliza Hall Institute of Medical Research, Parkville, Australia.
Maryam RashidiThe Walter and Eliza Hall Institute of Medical Research, Parkville, Australia.
Joanne M HildebrandThe Walter and Eliza Hall Institute of Medical Research, Parkville, Australia.ORCID 0000-0002-1456-2042
James M MurphyThe Walter and Eliza Hall Institute of Medical Research, Parkville, Australia.ORCID 0000-0003-0195-3949
Lachlan WhiteheadThe Walter and Eliza Hall Institute of Medical Research, Parkville, Australia.
David P De SouzaMetabolomics Australia, Bio21 Institute of Molecular Science and Biotechnology, University of Melbourne, Melbourne, Australia.
Seth L MastersThe Walter and Eliza Hall Institute of Medical Research, Parkville, Australia.
Andre L SamsonThe Walter and Eliza Hall Institute of Medical Research, Parkville, Australia.
Najoua LalaouiThe Walter and Eliza Hall Institute of Medical Research, Parkville, Australia.
Edwin D HawkinsThe Walter and Eliza Hall Institute of Medical Research, Parkville, Australia.
Andrew J MurphyBaker Heart and Diabetes Institute, Melbourne, Australia.
James E VinceThe Walter and Eliza Hall Institute of Medical Research, Parkville, Australia.
Kate E LawlorCentre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Australia kate.lawlor@hudson.org.au.ORCID 0000-0003-0471-6842

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cell death frequently occurs in the pathogenesis of obesity and metabolic dysfunction-associated fatty liver disease (MAFLD). However, the exact contribution of core cell death machinery to disease manifestations remains ill-defined. Here, we show via the direct comparison of mice genetically deficient in the essential necroptotic regulators, receptor-interacting protein kinase-3 (RIPK3) and mixed lineage kinase domain-like (MLKL), as well as mice lacking apoptotic caspase-8 in myeloid cells combined with RIPK3 loss, that RIPK3/caspase-8 signaling regulates macrophage inflammatory responses and drives adipose tissue inflammation and MAFLD upon high-fat diet feeding. In contrast, MLKL, divergent to RIPK3, contributes to both obesity and MAFLD in a manner largely independent of inflammation. We also uncover that MLKL regulates the expression of molecules involved in lipid uptake, transport, and metabolism, and congruent with this, we discover a shift in the hepatic lipidome upon MLKL deletion. Collectively, these findings highlight MLKL as an attractive therapeutic target to combat the growing obesity pandemic and metabolic disease.

Indexed as

Diet, High-FatObesityProtein KinasesReceptor-Interacting Protein Serine-Threonine KinasesAdipose TissueAnimalsApoptosisCaspase 8Fatty LiverInflammationLiverMacrophagesMaleMiceMice, Inbred C57BLMice, KnockoutCasp8 protein, mouseCaspase 8MLKL protein, mouseProtein KinasesReceptor-Interacting Protein Serine-Threonine KinasesRipk3 protein, mouse

Identifiers

PMID39532538
PMCPMC11557689

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.